# Dr. Reddy's

Biosimilars at scale — affordable biosimilar mAbs.


Source: https://en.bioecon.ru/companies/dr-reddys/
Updated: 2026-07-29

- Country: India

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | US$ 3.8 billion for fiscal year 2025 | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |
| Headcount | 26,944 employees globally as of March 31, 2025 | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |
| Capacity | 12 million vials and 18 million pre-filled syringes annually for biosimilars | https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| Production site | Hyderabad, India, including a cutting-edge biologics CDMO facility in Genome Valley | https://risecorp.co.in/where-are-dr-reddy-s-drugs-manufactured-inside-india-s-pharma-powerhouse, https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| Certification | 19 manufacturing facilities are ISO 45001 certified; facilities meet global quality standards with accreditations from regulatory bodies across Europe, Latin America, and other international markets | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf, https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| Regulatory approval | Received marketing authorisation for rituximab biosimilar in Europe (EMA) and UK (MHRA); BLA for denosumab biosimilar accepted by US FDA | https://www.drreddys.com/cms/cms/sites/default/files/2025-05/DRL_Q4FY25%20Earnings%20Call%20Transcript_9May2025.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-05/Earnings%20Release_Q4FY25_090525_Final1.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf, https://www.drreddysbiologics.com/biosimilars, https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm |
| Funding | The company invests approximately 8-10% of its annual revenues in R&D, with specific focus on building its biosimilars pipeline; a ₹10,000 crore national initiative (Biopharma SHAKTI) was launched in the Union Budget 2026 to strengthen India's biologics manufacturing ecosystem [medium confidence] | https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biosimilars-innovation-are-dr-reddys-growth-pill-generics-to-remain-core-business-says-co-chairman-md-gv-prasad/articleshow/128687416.cms, https://www.drreddys.com/cms/cms/sites/default/files/2025-05/DRL_Q4FY25%20Earnings%20Call%20Transcript_9May2025.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |

Independent sources: economictimes.indiatimes.com, risecorp.co.in, sec.gov

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)